349 related articles for article (PubMed ID: 32269053)
1. Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.
Yun MR; Kim DH; Kim SY; Joo HS; Lee YW; Choi HM; Park CW; Heo SG; Kang HN; Lee SS; Schoenfeld AJ; Drilon A; Kang SG; Shim HS; Hong MH; Cui JJ; Kim HR; Cho BC
Clin Cancer Res; 2020 Jul; 26(13):3287-3295. PubMed ID: 32269053
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles.
Terrones M; Deben C; Rodrigues-Fortes F; Schepers A; de Beeck KO; Van Camp G; Vandeweyer G
J Transl Med; 2024 Mar; 22(1):234. PubMed ID: 38433235
[TBL] [Abstract][Full Text] [Related]
3. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in
Lin JJ; Choudhury NJ; Yoda S; Zhu VW; Johnson TW; Sakhtemani R; Dagogo-Jack I; Digumarthy SR; Lee C; Do A; Peterson J; Prutisto-Chang K; Malik W; Hubbeling HG; Langenbucher A; Schoenfeld AJ; Falcon CJ; Temel JS; Sequist LV; Yeap BY; Lennerz JK; Shaw AT; Lawrence MS; Ou SI; Hata AN; Drilon A; Gainor JF
Clin Cancer Res; 2021 May; 27(10):2899-2909. PubMed ID: 33685866
[TBL] [Abstract][Full Text] [Related]
4. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Drilon A; Ou SI; Cho BC; Kim DW; Lee J; Lin JJ; Zhu VW; Ahn MJ; Camidge DR; Nguyen J; Zhai D; Deng W; Huang Z; Rogers E; Liu J; Whitten J; Lim JK; Stopatschinskaja S; Hyman DM; Doebele RC; Cui JJ; Shaw AT
Cancer Discov; 2018 Oct; 8(10):1227-1236. PubMed ID: 30093503
[TBL] [Abstract][Full Text] [Related]
5. Repotrectinib in
Drilon A; Camidge DR; Lin JJ; Kim SW; Solomon BJ; Dziadziuszko R; Besse B; Goto K; de Langen AJ; Wolf J; Lee KH; Popat S; Springfeld C; Nagasaka M; Felip E; Yang N; Velcheti V; Lu S; Kao S; Dooms C; Krebs MG; Yao W; Beg MS; Hu X; Moro-Sibilot D; Cheema P; Stopatschinskaja S; Mehta M; Trone D; Graber A; Sims G; Yuan Y; Cho BC;
N Engl J Med; 2024 Jan; 390(2):118-131. PubMed ID: 38197815
[TBL] [Abstract][Full Text] [Related]
6. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
[TBL] [Abstract][Full Text] [Related]
7. SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors.
Xia ZJ; Ji YC; Sun DQ; Peng X; Gao YL; Fang YF; Zhao XD; Wang WB; Ding J; Geng MY; Ai J
Acta Pharmacol Sin; 2021 Jun; 42(6):998-1004. PubMed ID: 32918045
[TBL] [Abstract][Full Text] [Related]
8. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Katayama R; Gong B; Togashi N; Miyamoto M; Kiga M; Iwasaki S; Kamai Y; Tominaga Y; Takeda Y; Kagoshima Y; Shimizu Y; Seto Y; Oh-Hara T; Koike S; Nakao N; Hanzawa H; Watanabe K; Yoda S; Yanagitani N; Hata AN; Shaw AT; Nishio M; Fujita N; Isoyama T
Nat Commun; 2019 Aug; 10(1):3604. PubMed ID: 31399568
[TBL] [Abstract][Full Text] [Related]
9. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
10. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Zou HY; Li Q; Engstrom LD; West M; Appleman V; Wong KA; McTigue M; Deng YL; Liu W; Brooun A; Timofeevski S; McDonnell SR; Jiang P; Falk MD; Lappin PB; Affolter T; Nichols T; Hu W; Lam J; Johnson TW; Smeal T; Charest A; Fantin VR
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3493-8. PubMed ID: 25733882
[TBL] [Abstract][Full Text] [Related]
11. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
12. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
13. Therapeutical Options in ROS1-Rearranged Advanced Non Small Cell Lung Cancer.
Stanzione B; Del Conte A; Bertoli E; De Carlo E; Revelant A; Spina M; Bearz A
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511255
[TBL] [Abstract][Full Text] [Related]
14. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Shaw AT; Solomon BJ; Chiari R; Riely GJ; Besse B; Soo RA; Kao S; Lin CC; Bauer TM; Clancy JS; Thurm H; Martini JF; Peltz G; Abbattista A; Li S; Ou SI
Lancet Oncol; 2019 Dec; 20(12):1691-1701. PubMed ID: 31669155
[TBL] [Abstract][Full Text] [Related]
15. ROS1 rearrangements define a unique molecular class of lung cancers.
Bergethon K; Shaw AT; Ou SH; Katayama R; Lovly CM; McDonald NT; Massion PP; Siwak-Tapp C; Gonzalez A; Fang R; Mark EJ; Batten JM; Chen H; Wilner KD; Kwak EL; Clark JW; Carbone DP; Ji H; Engelman JA; Mino-Kenudson M; Pao W; Iafrate AJ
J Clin Oncol; 2012 Mar; 30(8):863-70. PubMed ID: 22215748
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central β-Sheet 6 [Cβ6] Mutation [L2086F]).
Ou SI; Hagopian GG; Zhang SS; Nagasaka M
J Thorac Oncol; 2024 May; 19(5):706-718. PubMed ID: 38070596
[TBL] [Abstract][Full Text] [Related]
17. CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib.
Gou W; Zhou X; Liu Z; Wang L; Shen J; Xu X; Li Z; Zhai X; Zuo D; Wu Y
Cancer Lett; 2018 May; 422():19-28. PubMed ID: 29477381
[TBL] [Abstract][Full Text] [Related]
18. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Shaw AT; Ou SH; Bang YJ; Camidge DR; Solomon BJ; Salgia R; Riely GJ; Varella-Garcia M; Shapiro GI; Costa DB; Doebele RC; Le LP; Zheng Z; Tan W; Stephenson P; Shreeve SM; Tye LM; Christensen JG; Wilner KD; Clark JW; Iafrate AJ
N Engl J Med; 2014 Nov; 371(21):1963-71. PubMed ID: 25264305
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of Resistance to Tyrosine Kinase Inhibitors in ROS1 Fusion-Positive Nonsmall Cell Lung Cancer.
Zhao X; Zhang X; Chen H; Bao H; Wu X; Wang H; Bao H; Pang J; Wang S; Wang J
Clin Chem; 2024 Apr; 70(4):629-641. PubMed ID: 38416709
[TBL] [Abstract][Full Text] [Related]
20. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Remon J; Pignataro D; Novello S; Passiglia F
Cancer Treat Rev; 2021 Apr; 95():102178. PubMed ID: 33743408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
